PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

NAD+ Precursors (NMN & NR): Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for NAD+ Precursors (NMN & NR) across studied indications.

Back to NAD+ Precursors (NMN & NR) overview

Research Summary

NMN and NR have a combined 100+ human studies and 20+ RCTs demonstrating consistent NAD+ elevation of 40-100%. An NMN Phase 2 trial (n=80, PMID: 36482258) showed safe, dose-dependent NAD+ increases in healthy middle-aged adults. An NMN Phase 1 (n=25) demonstrated improved muscle function in older men. NR studies have shown improved insulin sensitivity and safety at doses up to 1,000 mg/day. The preclinical anti-aging data is compelling, but human evidence for lifespan extension or disease modification remains absent. Both are currently available as dietary supplements, though NMN's regulatory status is under FDA review.

Evidence by Indication (4 indications)

Indication Tier Trials Summary
NAD+ blood level elevation Tier A 20 Consistent 40-100% NAD+ increase across multiple RCTs for both NMN and NR
Muscle function improvement Tier C 2 Small Phase 1 trials show improved strength and walking speed in elderly
Metabolic health Tier C 5 Improved insulin sensitivity in overweight subjects; larger trials needed
Anti-aging / lifespan extension Tier D 0 Strong preclinical data but no human lifespan or disease modification evidence

Graded using our evidence tier methodology.

Citations (3 sources)

  1. 1. NMN dose-ranging study in healthy middle-aged adults Clinical Trial

    Yi L, Maier AB, et al. (2022), GeroScience

  2. 2. NMN supplementation and muscle function in older men Clinical Trial

    Igarashi M, Nakagawa-Nagahama Y, et al. (2022), NPJ Aging

  3. 3. Nicotinamide riboside is safely tolerated and elevates NAD+ in healthy volunteers Clinical Trial

    Airhart SE, Shireman LM, et al. (2017), PLoS ONE